Japanese Prime Minister Shinzo Abe Coroner is optimistic about Avignon's effectiveness. The Japanese government will send the drug-free of charge to COVID-19 patients in more than 20 countries, following Avignon's success in China as an antidote to the Coronavirus.
Unconfirmed results of the study showed that thirty-year-old patients appeared to be happy within seven days, even when the patient's PCR was negative. In the case of middle-aged people, joint use of Avignon and Orvosco has been reported to be smooth on day 7. However, due to the possibility of side effects from pregnant women, it was not implemented.
Avignon's generic name, Favipiravi, showed good results in the first two rounds of clinical trials. The coronary virus is believed to be the first proven treatment in Japan, with the success of 120 coronary-stricken patients in Japan, after successful implementation.
According to researchers, it can also have antivirus effects against the COVID-19 virus. Avigan, the chemical branch of Toyama, manufactures the drug, a subsidiary of giant Fujifilm. The drug was already approved in Japan to prevent the flu. Avignon did a great job of treating coronas in China.
Japan has been researching this drug for a long time. Avignon's clinical trial is currently underway with Japan's financial and technical assistance in 20 other countries. Japan has announced that it will pay for humanitarian aid to Corona treatment.
After some more tests, Japan has announced that Avigan is a fruitful herbal remedy for the treatment of coronas, and the company has increased its production in view of the global demand. In other countries, Japan has said it will allow production.

Comments